Side-by-side comparison of AI visibility scores, market position, and capabilities
London digital CBT app for tinnitus with DEFINE Trial evidence showing 86% benefit in one month; £2.8M seed competing with Widex and ReSound for 750M global tinnitus sufferers needing accessible specialist care.
Oto is a London-based digital health company providing clinically validated, app-based CBT (cognitive behavioral therapy) treatment for tinnitus — the persistent ringing, buzzing, or hissing in the ears that affects 15% of the global population (750 million+ people) with no pharmaceutical cure — delivering structured therapeutic programs designed by tinnitus specialists that help patients manage and reduce tinnitus distress through evidence-based psychological and sound therapy techniques. Founded and backed with £2.8 million in seed funding raised in 2022, Oto demonstrated in the DEFINE Trial (the largest randomized controlled trial for any digital tinnitus program) that 86% of users experience measurable benefits within one month of the program.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.